#SFHS2608292AOrder of April 10, 2026 Amending the List of Pharmaceutical Specialties Approved for Use by Communities and Various Public Services
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order updates the list of medicines approved for use by public institutions in France. It specifically adds two micafungin formulations from Accord Healthcare France to this list. Healthcare facilities can now use these drugs with costs covered by health insurance for approved therapeutic uses.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds two new micafungin formulations to the approved drug list
- Enables health insurance coverage for these drugs when used therapeutically
- Updates are reflected in public sector healthcare facilities
Obligations
What this law requires
Public healthcare institutions and communities must recognize MICAFUNGINE ACCORD 100 mg (CIP: 34009 302 871 9 4) and MICAFUNGINE ACCORD 50 mg (CIP: 34009 302 871 8 7) as approved pharmaceutical specialties for use within their facilities
Health insurance (assurance maladie) must cover costs for MICAFUNGINE ACCORD formulations only when prescribed for therapeutic indications listed in the current marketing authorization (AMM) at the time of this order's publication
Public institutions must limit reimbursement coverage of MICAFUNGINE ACCORD to the specific approved therapeutic indications defined in the marketing authorization, not for off-label uses
Accord Healthcare France SAS must ensure the listed formulations (100 mg and 50 mg) remain compliant with their respective marketing authorizations for continued approved status